<?xml version='1.0' encoding='UTF-8'?><?xml-stylesheet href="http://www.blogger.com/styles/atom.css" type="text/css"?><feed xmlns='http://www.w3.org/2005/Atom' xmlns:openSearch='http://a9.com/-/spec/opensearchrss/1.0/' xmlns:blogger='http://schemas.google.com/blogger/2008' xmlns:georss='http://www.georss.org/georss' xmlns:gd="http://schemas.google.com/g/2005" xmlns:thr='http://purl.org/syndication/thread/1.0'><id>tag:blogger.com,1999:blog-6133155209720004801</id><updated>2026-11-20T06:30:19.852-08:00</updated><title type='text'>CIENCIASMEDICASNEWS</title><subtitle type='html'>Aporte a la rutina de la trinchera asistencial donde los conocimientos se funden con las demandas de los pacientes, sus necesidades y las esperanzas de permanecer en la gracia de la SALUD.</subtitle><link rel='http://schemas.google.com/g/2005#feed' type='application/atom+xml' href='http://elbiruniblogspotcom.blogspot.com/feeds/posts/default'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default?redirect=false'/><link rel='alternate' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/'/><link rel='hub' href='http://pubsubhubbub.appspot.com/'/><link rel='next' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default?start-index=26&amp;max-results=25&amp;redirect=false'/><author><name>salud equitativa</name><uri>http://www.blogger.com/profile/07311128648250676366</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='29' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjP1bRvK6r5s9cdQYx6VnhhqYNzD_duyjJALHnoOaMe_O2NvjtFtZbrcVFdjehk2aYq4ID66zSiRhSMBe1afy52ty1Q4xMTT0lTlmQFKLe4qUnVHttO00MqeETdGsjyuw/s220/pagina69.jpg'/></author><generator version='7.00' uri='http://www.blogger.com'>Blogger</generator><openSearch:totalResults>193928</openSearch:totalResults><openSearch:startIndex>1</openSearch:startIndex><openSearch:itemsPerPage>25</openSearch:itemsPerPage><entry><id>tag:blogger.com,1999:blog-6133155209720004801.post-6617303787461773954</id><published>2026-11-20T06:30:19.851-08:00</published><updated>2026-11-20T06:30:19.852-08:00</updated><title type='text'>Emerging Therapies in Uveal Melanoma: Clinical Trial Updates Authors: Marlana Orloff, MD; Richard D. Carvajal, MD; Paul Nathan, PhD, FRCP</title><content type='html'>&lt;a href=&quot;https://www.medscape.org/viewarticle/emerging-therapies-uveal-melanoma-clinical-trial-updates-2026a1000t9y?page=1&amp;amp;src=mkmcmr_driv_stan_mscpedu_261119-OUS-HONC-emerging-therapies-uveal-melanoma-clinical-trial-updates-2026a1000t9y-cta&amp;amp;uac=148436CN&quot;&gt;https://www.medscape.org/viewarticle/emerging-therapies-uveal-melanoma-clinical-trial-updates-2026a1000t9y?page=1&amp;src=mkmcmr_driv_stan_mscpedu_261119-OUS-HONC-emerging-therapies-uveal-melanoma-clinical-trial-updates-2026a1000t9y-cta&amp;uac=148436CN&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='http://elbiruniblogspotcom.blogspot.com/feeds/6617303787461773954/comments/default' title='Enviar comentarios'/><link rel='replies' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/emerging-therapies-in-uveal-melanoma.html#comment-form' title='0 comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/6617303787461773954'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/6617303787461773954'/><link rel='alternate' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/emerging-therapies-in-uveal-melanoma.html' title='Emerging Therapies in Uveal Melanoma: Clinical Trial Updates Authors: Marlana Orloff, MD; Richard D. Carvajal, MD; Paul Nathan, PhD, FRCP'/><author><name>salud equitativa</name><uri>http://www.blogger.com/profile/07311128648250676366</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='29' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjP1bRvK6r5s9cdQYx6VnhhqYNzD_duyjJALHnoOaMe_O2NvjtFtZbrcVFdjehk2aYq4ID66zSiRhSMBe1afy52ty1Q4xMTT0lTlmQFKLe4qUnVHttO00MqeETdGsjyuw/s220/pagina69.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6133155209720004801.post-559409074458038642</id><published>2026-11-20T06:28:27.430-08:00</published><updated>2026-11-20T06:28:27.430-08:00</updated><title type='text'>Next-Generation Gadolinium-Based Contrast Agents in MRI: Quickfire Answers to Your Top Questions Authors: Taryn Winter Brill; Katja Pinker-Domenig, MD, PhD; Dipan J. Shah, MD, FACC</title><content type='html'>&lt;a href=&quot;https://www.medscape.org/viewarticle/next-generation-gadolinium-based-contrast-agents-mri-2026a1000xjl?page=1&amp;amp;uac=148436CN&amp;amp;src=mkmcmr_driv_stan_mscpedu_261119-OUS-HONC-next-generation-gadolinium-based-contrast-agents-mri-2026a1000xjl-cta&quot;&gt;https://www.medscape.org/viewarticle/next-generation-gadolinium-based-contrast-agents-mri-2026a1000xjl?page=1&amp;uac=148436CN&amp;src=mkmcmr_driv_stan_mscpedu_261119-OUS-HONC-next-generation-gadolinium-based-contrast-agents-mri-2026a1000xjl-cta&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='http://elbiruniblogspotcom.blogspot.com/feeds/559409074458038642/comments/default' title='Enviar comentarios'/><link rel='replies' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/next-generation-gadolinium-based.html#comment-form' title='0 comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/559409074458038642'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/559409074458038642'/><link rel='alternate' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/next-generation-gadolinium-based.html' title='Next-Generation Gadolinium-Based Contrast Agents in MRI: Quickfire Answers to Your Top Questions Authors: Taryn Winter Brill; Katja Pinker-Domenig, MD, PhD; Dipan J. Shah, MD, FACC'/><author><name>salud equitativa</name><uri>http://www.blogger.com/profile/07311128648250676366</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='29' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjP1bRvK6r5s9cdQYx6VnhhqYNzD_duyjJALHnoOaMe_O2NvjtFtZbrcVFdjehk2aYq4ID66zSiRhSMBe1afy52ty1Q4xMTT0lTlmQFKLe4qUnVHttO00MqeETdGsjyuw/s220/pagina69.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6133155209720004801.post-1666976756571249267</id><published>2026-11-20T06:26:49.905-08:00</published><updated>2026-11-20T06:26:49.906-08:00</updated><title type='text'>Conversations on Pain: Determining the Causes, Making a Plan, and Considering Nonopioid Analgesics Authors: Jeff Gudin, MD; Timothy J. Atkinson, PharmD, CPE; Antje Barreveld, MD; Mark Garofoli, PharmD, MBA, BCGP, CPE, CTTS; Steven P. Stanos, DO</title><content type='html'>&lt;a href=&quot;https://www.medscape.org/viewarticle/conversations-pain-determining-causes-making-plan-and-2025a1000wsc?page=1&amp;amp;uac=148436CN&amp;amp;src=mkm_driv_cust_mscpedu_261119-12110769&quot;&gt;https://www.medscape.org/viewarticle/conversations-pain-determining-causes-making-plan-and-2025a1000wsc?page=1&amp;uac=148436CN&amp;src=mkm_driv_cust_mscpedu_261119-12110769&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='http://elbiruniblogspotcom.blogspot.com/feeds/1666976756571249267/comments/default' title='Enviar comentarios'/><link rel='replies' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/conversations-on-pain-determining.html#comment-form' title='0 comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/1666976756571249267'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/1666976756571249267'/><link rel='alternate' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/conversations-on-pain-determining.html' title='Conversations on Pain: Determining the Causes, Making a Plan, and Considering Nonopioid Analgesics Authors: Jeff Gudin, MD; Timothy J. Atkinson, PharmD, CPE; Antje Barreveld, MD; Mark Garofoli, PharmD, MBA, BCGP, CPE, CTTS; Steven P. Stanos, DO'/><author><name>salud equitativa</name><uri>http://www.blogger.com/profile/07311128648250676366</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='29' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjP1bRvK6r5s9cdQYx6VnhhqYNzD_duyjJALHnoOaMe_O2NvjtFtZbrcVFdjehk2aYq4ID66zSiRhSMBe1afy52ty1Q4xMTT0lTlmQFKLe4qUnVHttO00MqeETdGsjyuw/s220/pagina69.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6133155209720004801.post-5259641331485301758</id><published>2026-11-20T06:25:27.246-08:00</published><updated>2026-11-20T06:25:27.246-08:00</updated><title type='text'>A consensus to stall on biodiversity The Lancet Planetary Health (++...)</title><content type='html'>&lt;b&gt;A consensus to stall on biodiversity
The Lancet Planetary Health&lt;/b&gt;
&lt;a href=&quot;https://www.thelancet.com/journals/lanplh/article/PIIS2542-5196%2826%2900141-5/fulltext?dgcid=raven_jbs_etoc_email&quot;&gt;https://www.thelancet.com/journals/lanplh/article/PIIS2542-5196(26)00141-5/fulltext?dgcid=raven_jbs_etoc_email&lt;/a&gt;
In October this year, representatives met for the 17th Conference of the Parties to the Convention on Biological Diversity, and the results were to most a disappointment.
The Convention — established in 1993 and signed by almost every country in the world — recognised more than 20 years ago that global biodiversity was in serious decline, and it was meant to provide the leading multilateral forum to solve that problem. Unfortunately, despite the recognition that biodiversity is essential to human health and wellbeing, it remains overall in decline.
In 2010 countries negotiated the Aichi targets to protect and restore global biodiversity over the next decade, but by 2020 most of the targets remained unmet. This failure was blamed on the vagueness of the targets, not providing ways to monitor progress, and no clear plan to finance implementation.
&lt;a href=&quot;https://www.thelancet.com/journals/lanplh/issue/vol10no10/PIIS2542-5196%2826%29X2010-1&quot;&gt;https://www.thelancet.com/journals/lanplh/issue/vol10no10/PIIS2542-5196(26)X2010-1&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='http://elbiruniblogspotcom.blogspot.com/feeds/5259641331485301758/comments/default' title='Enviar comentarios'/><link rel='replies' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/a-consensus-to-stall-on-biodiversity.html#comment-form' title='0 comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/5259641331485301758'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/5259641331485301758'/><link rel='alternate' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/a-consensus-to-stall-on-biodiversity.html' title='A consensus to stall on biodiversity The Lancet Planetary Health (++...)'/><author><name>salud equitativa</name><uri>http://www.blogger.com/profile/07311128648250676366</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='29' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjP1bRvK6r5s9cdQYx6VnhhqYNzD_duyjJALHnoOaMe_O2NvjtFtZbrcVFdjehk2aYq4ID66zSiRhSMBe1afy52ty1Q4xMTT0lTlmQFKLe4qUnVHttO00MqeETdGsjyuw/s220/pagina69.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6133155209720004801.post-8808175220000382670</id><published>2026-11-20T06:23:27.780-08:00</published><updated>2026-11-20T06:23:27.781-08:00</updated><title type='text'>Multiple sclerosis: beyond controlling relapses The Lancet (++...)</title><content type='html'>&lt;b&gt;Multiple sclerosis: beyond controlling relapses
The Lancet&lt;/b&gt;
&lt;a href=&quot;https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2902345-7/fulltext?dgcid=raven_jbs_etoc_email&quot;&gt;https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)02345-7/fulltext?dgcid=raven_jbs_etoc_email&lt;/a&gt;
Few neurological diseases have seen a transformation in diagnosis and treatment as remarkable as multiple sclerosis. A chronic, heterogeneous autoimmune condition, it typically begins in early adulthood and affects over 3 million people, with women roughly three times more likely to be affected than men. Characterised by inflammation, demyelination, axonal injury, and neuronal loss, multiple sclerosis can cause relapses and gradual accumulation of disability. Three decades ago, treatment options were few and far between; today, more than 20 disease-modifying therapies are available. These therapies can reduce the frequency of relapses and the development of new lesions detected with MRI. However, the success in controlling relapses has brought to light another challenge: despite otherwise effective treatment, some patients continue to accumulate disability.
&lt;a href=&quot;https://www.thelancet.com/journals/lancet/issue/vol408no10569/PIIS0140-6736%2826%29X2044-X&quot;&gt;https://www.thelancet.com/journals/lancet/issue/vol408no10569/PIIS0140-6736(26)X2044-X&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='http://elbiruniblogspotcom.blogspot.com/feeds/8808175220000382670/comments/default' title='Enviar comentarios'/><link rel='replies' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/multiple-sclerosis-beyond-controlling.html#comment-form' title='0 comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/8808175220000382670'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/8808175220000382670'/><link rel='alternate' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/multiple-sclerosis-beyond-controlling.html' title='Multiple sclerosis: beyond controlling relapses The Lancet (++...)'/><author><name>salud equitativa</name><uri>http://www.blogger.com/profile/07311128648250676366</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='29' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjP1bRvK6r5s9cdQYx6VnhhqYNzD_duyjJALHnoOaMe_O2NvjtFtZbrcVFdjehk2aYq4ID66zSiRhSMBe1afy52ty1Q4xMTT0lTlmQFKLe4qUnVHttO00MqeETdGsjyuw/s220/pagina69.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6133155209720004801.post-3243691208241269863</id><published>2026-11-20T05:18:19.455-08:00</published><updated>2026-11-20T05:18:19.455-08:00</updated><title type='text'>Oncology Perspective:  Should Patients Have to Go on TV to Access Cancer Drugs?​ </title><content type='html'>&lt;b&gt;Oncology Perspective

Should Patients Have to Go on TV to Access Cancer Drugs?​&lt;/b&gt;
Televised appeals for promising cancer drugs raise questions regarding equitable access, regional inequalities, and fair allocation of public healthcare resources.
Medscape Europe, November 20, 2026
&lt;a href=&quot;https://www.medscape.com/index/list_13293_0&quot;&gt;https://www.medscape.com/index/list_13293_0&lt;/a&gt;
</content><link rel='replies' type='application/atom+xml' href='http://elbiruniblogspotcom.blogspot.com/feeds/3243691208241269863/comments/default' title='Enviar comentarios'/><link rel='replies' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/oncology-perspective-should-patients.html#comment-form' title='0 comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/3243691208241269863'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/3243691208241269863'/><link rel='alternate' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/oncology-perspective-should-patients.html' title='Oncology Perspective:  Should Patients Have to Go on TV to Access Cancer Drugs?​ '/><author><name>salud equitativa</name><uri>http://www.blogger.com/profile/07311128648250676366</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='29' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjP1bRvK6r5s9cdQYx6VnhhqYNzD_duyjJALHnoOaMe_O2NvjtFtZbrcVFdjehk2aYq4ID66zSiRhSMBe1afy52ty1Q4xMTT0lTlmQFKLe4qUnVHttO00MqeETdGsjyuw/s220/pagina69.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6133155209720004801.post-3159631820410993695</id><published>2026-11-20T05:16:45.612-08:00</published><updated>2026-11-20T05:16:45.612-08:00</updated><title type='text'>Oncology News:  Blinatumomab Feasible for Children With Leukemia in LMICs (+...)</title><content type='html'>&lt;b&gt;Oncology News

Blinatumomab Feasible for Children With Leukemia in LMICs&lt;/b&gt;
A real-world study examines whether blinatumomab can be given safely and effectively to children with B-cell acute lymphoblastic leukemia at referral hospitals in lower-middle-income countries.
Medscape Medical News, November 20, 2026
&lt;a href=&quot;https://www.medscape.com/index/list_13474_0&quot;&gt;https://www.medscape.com/index/list_13474_0&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='http://elbiruniblogspotcom.blogspot.com/feeds/3159631820410993695/comments/default' title='Enviar comentarios'/><link rel='replies' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/oncology-news-blinatumomab-feasible-for.html#comment-form' title='0 comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/3159631820410993695'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/3159631820410993695'/><link rel='alternate' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/oncology-news-blinatumomab-feasible-for.html' title='Oncology News:  Blinatumomab Feasible for Children With Leukemia in LMICs (+...)'/><author><name>salud equitativa</name><uri>http://www.blogger.com/profile/07311128648250676366</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='29' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjP1bRvK6r5s9cdQYx6VnhhqYNzD_duyjJALHnoOaMe_O2NvjtFtZbrcVFdjehk2aYq4ID66zSiRhSMBe1afy52ty1Q4xMTT0lTlmQFKLe4qUnVHttO00MqeETdGsjyuw/s220/pagina69.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6133155209720004801.post-9010839560734988247</id><published>2026-11-20T05:14:23.748-08:00</published><updated>2026-11-20T05:14:23.748-08:00</updated><title type='text'>Rett Syndrome</title><content type='html'>&lt;b&gt;Rett Syndrome&lt;/b&gt;
Rett syndrome is a rare, progressive neurodevelopmental disorder and a leading cause of severe intellectual disability in girls. Early diagnosis enables timely intervention, shifting care from supportive symptom management to emerging targeted therapies.
&lt;a href=&quot;https://www.medscape.org/advances/clinical-advances-rett-syndrome-2025a10007af&quot;&gt;https://www.medscape.org/advances/clinical-advances-rett-syndrome-2025a10007af&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='http://elbiruniblogspotcom.blogspot.com/feeds/9010839560734988247/comments/default' title='Enviar comentarios'/><link rel='replies' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/rett-syndrome.html#comment-form' title='0 comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/9010839560734988247'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/9010839560734988247'/><link rel='alternate' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/rett-syndrome.html' title='Rett Syndrome'/><author><name>salud equitativa</name><uri>http://www.blogger.com/profile/07311128648250676366</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='29' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjP1bRvK6r5s9cdQYx6VnhhqYNzD_duyjJALHnoOaMe_O2NvjtFtZbrcVFdjehk2aYq4ID66zSiRhSMBe1afy52ty1Q4xMTT0lTlmQFKLe4qUnVHttO00MqeETdGsjyuw/s220/pagina69.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6133155209720004801.post-4992939967725966509</id><published>2026-11-20T05:12:52.614-08:00</published><updated>2026-11-20T05:12:52.614-08:00</updated><title type='text'>Colorectal Cancer Update: Integrating Emerging Science From the Annual European Oncology Meeting Into Community Practice Authors: Tiago Biachi de Castria, MD, PhD </title><content type='html'>&lt;a href=&quot;https://www.medscape.org/viewarticle/colorectal-cancer-update-integrating-emerging-science-annual-2026a10016yz?page=1&quot;&gt;https://www.medscape.org/viewarticle/colorectal-cancer-update-integrating-emerging-science-annual-2026a10016yz?page=1&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='http://elbiruniblogspotcom.blogspot.com/feeds/4992939967725966509/comments/default' title='Enviar comentarios'/><link rel='replies' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/colorectal-cancer-update-integrating.html#comment-form' title='0 comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/4992939967725966509'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/4992939967725966509'/><link rel='alternate' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/colorectal-cancer-update-integrating.html' title='Colorectal Cancer Update: Integrating Emerging Science From the Annual European Oncology Meeting Into Community Practice Authors: Tiago Biachi de Castria, MD, PhD '/><author><name>salud equitativa</name><uri>http://www.blogger.com/profile/07311128648250676366</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='29' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjP1bRvK6r5s9cdQYx6VnhhqYNzD_duyjJALHnoOaMe_O2NvjtFtZbrcVFdjehk2aYq4ID66zSiRhSMBe1afy52ty1Q4xMTT0lTlmQFKLe4qUnVHttO00MqeETdGsjyuw/s220/pagina69.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6133155209720004801.post-8288970996182653389</id><published>2026-11-20T05:12:09.546-08:00</published><updated>2026-11-20T05:12:09.546-08:00</updated><title type='text'>Adjuvant Immunotherapy in High-Risk CSCC: What’s New, What’s Next, What Clinicians Need to Know Authors: Anna C. Pavlick, DO, MBA; Nina A. Ran, MD, MS, MPH </title><content type='html'>&lt;a href=&quot;https://www.medscape.org/viewarticle/adjuvant-immunotherapy-high-risk-cscc-whats-new-whats-next-2026a10016zn?page=1&quot;&gt;https://www.medscape.org/viewarticle/adjuvant-immunotherapy-high-risk-cscc-whats-new-whats-next-2026a10016zn?page=1&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='http://elbiruniblogspotcom.blogspot.com/feeds/8288970996182653389/comments/default' title='Enviar comentarios'/><link rel='replies' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/adjuvant-immunotherapy-in-high-risk_0929647040.html#comment-form' title='0 comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/8288970996182653389'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/8288970996182653389'/><link rel='alternate' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/adjuvant-immunotherapy-in-high-risk_0929647040.html' title='Adjuvant Immunotherapy in High-Risk CSCC: What’s New, What’s Next, What Clinicians Need to Know Authors: Anna C. Pavlick, DO, MBA; Nina A. Ran, MD, MS, MPH '/><author><name>salud equitativa</name><uri>http://www.blogger.com/profile/07311128648250676366</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='29' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjP1bRvK6r5s9cdQYx6VnhhqYNzD_duyjJALHnoOaMe_O2NvjtFtZbrcVFdjehk2aYq4ID66zSiRhSMBe1afy52ty1Q4xMTT0lTlmQFKLe4qUnVHttO00MqeETdGsjyuw/s220/pagina69.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6133155209720004801.post-3056189486771674452</id><published>2026-11-20T05:11:18.366-08:00</published><updated>2026-11-20T05:11:18.367-08:00</updated><title type='text'>Eltrombopag Plus Cyclosporine for Moderate Aplastic Anemia: A Placebo-Controlled, Double-Blind Phase 3 Trial Authors: Britta Höchsmann, MD; Philippe Schafhausen, MD; Fabian Beier, MD; Michael Heuser, MD; Jörg Westermann, MD; Beatrice Drexler, MD; Alexander Röth, MD; Regina Herbst, MD; Mathias Hänel, MD; Michaela Schwarz, MD; Flore Sicre de Fontbrune, MD; Regis Peffault de Latour, MD, PhD; Astrid Marx-Hofmann, MD; Antonia Beitzen-Heineke, MD; Jens Panse, MD; Felicitas Thol, MD; Sixten Körper, MD; Tim H. Brümmendorf, MD; Hubert Schrezenmeier, MD</title><content type='html'>&lt;a href=&quot;https://www.medscape.org/viewarticle/eltrombopag-plus-cyclosporine-moderate-aplastic-anemia-2026a10018f1?page=1&quot;&gt;https://www.medscape.org/viewarticle/eltrombopag-plus-cyclosporine-moderate-aplastic-anemia-2026a10018f1?page=1&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='http://elbiruniblogspotcom.blogspot.com/feeds/3056189486771674452/comments/default' title='Enviar comentarios'/><link rel='replies' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/eltrombopag-plus-cyclosporine-for.html#comment-form' title='0 comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/3056189486771674452'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/3056189486771674452'/><link rel='alternate' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/eltrombopag-plus-cyclosporine-for.html' title='Eltrombopag Plus Cyclosporine for Moderate Aplastic Anemia: A Placebo-Controlled, Double-Blind Phase 3 Trial Authors: Britta Höchsmann, MD; Philippe Schafhausen, MD; Fabian Beier, MD; Michael Heuser, MD; Jörg Westermann, MD; Beatrice Drexler, MD; Alexander Röth, MD; Regina Herbst, MD; Mathias Hänel, MD; Michaela Schwarz, MD; Flore Sicre de Fontbrune, MD; Regis Peffault de Latour, MD, PhD; Astrid Marx-Hofmann, MD; Antonia Beitzen-Heineke, MD; Jens Panse, MD; Felicitas Thol, MD; Sixten Körper, MD; Tim H. Brümmendorf, MD; Hubert Schrezenmeier, MD'/><author><name>salud equitativa</name><uri>http://www.blogger.com/profile/07311128648250676366</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='29' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjP1bRvK6r5s9cdQYx6VnhhqYNzD_duyjJALHnoOaMe_O2NvjtFtZbrcVFdjehk2aYq4ID66zSiRhSMBe1afy52ty1Q4xMTT0lTlmQFKLe4qUnVHttO00MqeETdGsjyuw/s220/pagina69.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6133155209720004801.post-7088370462006736836</id><published>2026-11-20T05:09:48.831-08:00</published><updated>2026-11-20T05:09:48.831-08:00</updated><title type='text'>Modern Gastrointestinal Cancer Therapies</title><content type='html'>&lt;b&gt;Modern Gastrointestinal Cancer Therapies&lt;/b&gt;
As the therapeutic landscape for treating gastrointestinal cancer continues to grow and evolve, it is crucial for the oncology care team to remain up to date with the latest information. Our platform provides up-to-date resources to help optimize outcomes for your patients.
&lt;a href=&quot;https://www.medscape.org/advances/modern-gastrointestinal-cancer-therapies-2025a1000cys&quot;&gt;https://www.medscape.org/advances/modern-gastrointestinal-cancer-therapies-2025a1000cys&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='http://elbiruniblogspotcom.blogspot.com/feeds/7088370462006736836/comments/default' title='Enviar comentarios'/><link rel='replies' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/modern-gastrointestinal-cancer-therapies.html#comment-form' title='0 comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/7088370462006736836'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/7088370462006736836'/><link rel='alternate' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/modern-gastrointestinal-cancer-therapies.html' title='Modern Gastrointestinal Cancer Therapies'/><author><name>salud equitativa</name><uri>http://www.blogger.com/profile/07311128648250676366</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='29' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjP1bRvK6r5s9cdQYx6VnhhqYNzD_duyjJALHnoOaMe_O2NvjtFtZbrcVFdjehk2aYq4ID66zSiRhSMBe1afy52ty1Q4xMTT0lTlmQFKLe4qUnVHttO00MqeETdGsjyuw/s220/pagina69.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6133155209720004801.post-7168424928798141253</id><published>2026-11-20T05:08:41.287-08:00</published><updated>2026-11-20T05:08:41.288-08:00</updated><title type='text'>Immunotherapy in Locally Advanced Head and Neck Cancer: Evidence, Impact, and Integration Authors: Hisham Mehanna, FMedSci, PhD, BMedSc (hons), MB ChB (hons), FRCS, FRCS (ORL-HNS); Robert Haddad, MD </title><content type='html'>&lt;a href=&quot;https://www.medscape.org/viewarticle/immunotherapy-locally-advanced-head-and-neck-cancer-evidence-2026a1000khq?page=1&amp;amp;uac=148436CN&amp;amp;sso=true&amp;amp;src=mkmcmr_driv_stan_mscpedu_261120-OUS-HONC-immunotherapy-locally-advanced-head-and-neck-cancer-evidence-2026a1000khq-cta&quot;&gt;https://www.medscape.org/viewarticle/immunotherapy-locally-advanced-head-and-neck-cancer-evidence-2026a1000khq?page=1&amp;uac=148436CN&amp;sso=true&amp;src=mkmcmr_driv_stan_mscpedu_261120-OUS-HONC-immunotherapy-locally-advanced-head-and-neck-cancer-evidence-2026a1000khq-cta&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='http://elbiruniblogspotcom.blogspot.com/feeds/7168424928798141253/comments/default' title='Enviar comentarios'/><link rel='replies' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/immunotherapy-in-locally-advanced-head_01119806550.html#comment-form' title='0 comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/7168424928798141253'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/7168424928798141253'/><link rel='alternate' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/immunotherapy-in-locally-advanced-head_01119806550.html' title='Immunotherapy in Locally Advanced Head and Neck Cancer: Evidence, Impact, and Integration Authors: Hisham Mehanna, FMedSci, PhD, BMedSc (hons), MB ChB (hons), FRCS, FRCS (ORL-HNS); Robert Haddad, MD '/><author><name>salud equitativa</name><uri>http://www.blogger.com/profile/07311128648250676366</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='29' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjP1bRvK6r5s9cdQYx6VnhhqYNzD_duyjJALHnoOaMe_O2NvjtFtZbrcVFdjehk2aYq4ID66zSiRhSMBe1afy52ty1Q4xMTT0lTlmQFKLe4qUnVHttO00MqeETdGsjyuw/s220/pagina69.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6133155209720004801.post-7517094067359905333</id><published>2026-11-19T09:25:19.053-08:00</published><updated>2026-11-19T09:25:19.054-08:00</updated><title type='text'>Tissue regeneration to help healing</title><content type='html'>&lt;b&gt;Tissue regeneration to help healing
Replacing damaged cells to treat injury and disease &lt;/b&gt;
To stay alive, we have to replace cells that aren’t doing their job well, a process called regeneration. This Research in Context feature examines some of the ways NIH-supported scientists are trying to help our bodies do that through regenerative medicine. 
&lt;a href=&quot;https://www.nih.gov/news-events/nih-research-matters/tissue-regeneration-help-healing&quot;&gt;https://www.nih.gov/news-events/nih-research-matters/tissue-regeneration-help-healing&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='http://elbiruniblogspotcom.blogspot.com/feeds/7517094067359905333/comments/default' title='Enviar comentarios'/><link rel='replies' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/tissue-regeneration-to-help-healing.html#comment-form' title='0 comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/7517094067359905333'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/7517094067359905333'/><link rel='alternate' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/tissue-regeneration-to-help-healing.html' title='Tissue regeneration to help healing'/><author><name>salud equitativa</name><uri>http://www.blogger.com/profile/07311128648250676366</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='29' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjP1bRvK6r5s9cdQYx6VnhhqYNzD_duyjJALHnoOaMe_O2NvjtFtZbrcVFdjehk2aYq4ID66zSiRhSMBe1afy52ty1Q4xMTT0lTlmQFKLe4qUnVHttO00MqeETdGsjyuw/s220/pagina69.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6133155209720004801.post-5370291358047354389</id><published>2026-11-19T09:22:43.043-08:00</published><updated>2026-11-19T09:22:43.043-08:00</updated><title type='text'>Our Innate Immune System Protects Us More Than We Knew</title><content type='html'>&lt;a href=&quot;https://www.medscape.com/s/viewarticle/our-innate-immune-system-protects-us-more-than-we-knew-2026a10018n4?ecd=wnl_edit_tpal_etid8914816&amp;amp;uac=148436CN&amp;amp;impID=8914816&quot;&gt;https://www.medscape.com/s/viewarticle/our-innate-immune-system-protects-us-more-than-we-knew-2026a10018n4?ecd=wnl_edit_tpal_etid8914816&amp;uac=148436CN&amp;impID=8914816&lt;/a&gt;
Our immune system has long been described as consisting of two parts. There’s the “innate” part that acts as a first-line defense but is often considered a blunt tool that responds to each threat the same way. And there’s the slow-acting “adaptive” part that remembers the microbes it encounters and builds lasting immunity against them.</content><link rel='replies' type='application/atom+xml' href='http://elbiruniblogspotcom.blogspot.com/feeds/5370291358047354389/comments/default' title='Enviar comentarios'/><link rel='replies' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/our-innate-immune-system-protects-us.html#comment-form' title='0 comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/5370291358047354389'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/5370291358047354389'/><link rel='alternate' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/our-innate-immune-system-protects-us.html' title='Our Innate Immune System Protects Us More Than We Knew'/><author><name>salud equitativa</name><uri>http://www.blogger.com/profile/07311128648250676366</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='29' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjP1bRvK6r5s9cdQYx6VnhhqYNzD_duyjJALHnoOaMe_O2NvjtFtZbrcVFdjehk2aYq4ID66zSiRhSMBe1afy52ty1Q4xMTT0lTlmQFKLe4qUnVHttO00MqeETdGsjyuw/s220/pagina69.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6133155209720004801.post-8610730174028008840</id><published>2026-11-19T09:21:08.379-08:00</published><updated>2026-11-19T09:21:08.379-08:00</updated><title type='text'>After a GLP-1: Which Exit Strategy Keeps the Weight Off?</title><content type='html'>&lt;a href=&quot;https://www.medscape.com/viewarticle/after-glp-1-which-exit-strategy-keeps-weight-2026a10018gh?ecd=WNL_trdalrt_pos1_ous_261118_etid8915401&amp;amp;uac=148436CN&amp;amp;impID=8915401&quot;&gt;https://www.medscape.com/viewarticle/after-glp-1-which-exit-strategy-keeps-weight-2026a10018gh?ecd=WNL_trdalrt_pos1_ous_261118_etid8915401&amp;uac=148436CN&amp;impID=8915401&lt;/a&gt;
NATIONAL HARBOR, Md. — Among more than 20,000 patients who had taken semaglutide or tirzepatide, those who went on to pursue bariatric surgery, though the least likely choice, had the greatest weight loss after 2 years, while those who stopped treatment altogether had the least, new data show.

“To our knowledge, this is the first study to compare weight change and cardiometabolic parameters across several obesity treatment strategies in patients who initially took injectable semaglutide or tirzepatide for obesity or type 2 diabetes,” Hamlet Gasoyan, DS, PhD, MPH, assistant professor of medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Ohio, told Medscape Medical News.  </content><link rel='replies' type='application/atom+xml' href='http://elbiruniblogspotcom.blogspot.com/feeds/8610730174028008840/comments/default' title='Enviar comentarios'/><link rel='replies' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/after-glp-1-which-exit-strategy-keeps.html#comment-form' title='0 comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/8610730174028008840'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/8610730174028008840'/><link rel='alternate' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/after-glp-1-which-exit-strategy-keeps.html' title='After a GLP-1: Which Exit Strategy Keeps the Weight Off?'/><author><name>salud equitativa</name><uri>http://www.blogger.com/profile/07311128648250676366</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='29' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjP1bRvK6r5s9cdQYx6VnhhqYNzD_duyjJALHnoOaMe_O2NvjtFtZbrcVFdjehk2aYq4ID66zSiRhSMBe1afy52ty1Q4xMTT0lTlmQFKLe4qUnVHttO00MqeETdGsjyuw/s220/pagina69.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6133155209720004801.post-8654800930556844480</id><published>2026-11-19T09:19:34.575-08:00</published><updated>2026-11-19T09:19:34.576-08:00</updated><title type='text'>Diagnosing diabetes: the earlier the better The Lancet Diabetes &amp; Endocrinology (++...)</title><content type='html'>&lt;b&gt;Diagnosing diabetes: the earlier the better
The Lancet Diabetes &amp; Endocrinology&lt;/b&gt;
&lt;a href=&quot;https://www.thelancet.com/journals/landia/article/PIIS2213-8587%2826%2900277-9/fulltext?dgcid=raven_jbs_etoc_email&quot;&gt;https://www.thelancet.com/journals/landia/article/PIIS2213-8587(26)00277-9/fulltext?dgcid=raven_jbs_etoc_email&lt;/a&gt;
In 2021, WHO launched the Global Diabetes Compact, an initiative aimed at reducing the risk of diabetes and ensuring that all people diagnosed with the condition have access to equitable, affordable, and high-quality care. The following year, the 75th World Health Assembly adopted the Compact&#39;s global diabetes coverage targets to be achieved by 2030—80% to be diagnosed; 80% to have good glycaemic control; 80% to have good blood pressure control; 60% of those aged 40 years and older to be receiving statins; and 100% of people with type 1 diabetes to have access to affordable insulin and blood glucose self-monitoring supplies. The need for such ambitious targets was borne out by a 2026 pooled analysis of individual-level data from national surveys in 100 low-income, middle-income, and high-income countries. The study found that, in 2021, of the included countries, only 8 met the target for diagnosis, 7 for glycaemic control, 15 for blood pressure control, and 8 for statin use, with attainment levels for all metrics lowest in low-income and middle-income countries (LMICs). If the 2030 targets are to be met, inequalities in attainment must be reduced and substantial progress made across all countries.
&lt;a href=&quot;https://www.thelancet.com/journals/landia/issue/vol14no12/PIIS2213-8587%2826%29X2010-1&quot;&gt;https://www.thelancet.com/journals/landia/issue/vol14no12/PIIS2213-8587(26)X2010-1&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='http://elbiruniblogspotcom.blogspot.com/feeds/8654800930556844480/comments/default' title='Enviar comentarios'/><link rel='replies' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/diagnosing-diabetes-earlier-better.html#comment-form' title='0 comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/8654800930556844480'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/8654800930556844480'/><link rel='alternate' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/diagnosing-diabetes-earlier-better.html' title='Diagnosing diabetes: the earlier the better The Lancet Diabetes &amp; Endocrinology (++...)'/><author><name>salud equitativa</name><uri>http://www.blogger.com/profile/07311128648250676366</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='29' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjP1bRvK6r5s9cdQYx6VnhhqYNzD_duyjJALHnoOaMe_O2NvjtFtZbrcVFdjehk2aYq4ID66zSiRhSMBe1afy52ty1Q4xMTT0lTlmQFKLe4qUnVHttO00MqeETdGsjyuw/s220/pagina69.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6133155209720004801.post-7082209316798963181</id><published>2026-11-19T09:16:35.394-08:00</published><updated>2026-11-19T09:16:35.394-08:00</updated><title type='text'>Voices in Care: Multidisciplinary and Patient Perspectives on Advanced/Recurrent Endometrial Cancer Authors: Eva-Maria Strömsholm; Rebecca Kristeleit, MBChB, MRCP, PhD; Domenica Lorusso, MD, PhD; Antonio González-Martín, MD, PhD; Claire Lusted, ANP </title><content type='html'>&lt;a href=&quot;https://www.medscape.org/viewarticle/voices-care-multidisciplinary-and-patient-perspectives-2026a1000hui?page=1&amp;amp;src=mkmcmr_driv_stan_mscpedu_261118-OUS-HONC-voices-care-multidisciplinary-and-patient-perspectives-2026a1000hui-cta&amp;amp;uac=148436CN&quot;&gt;https://www.medscape.org/viewarticle/voices-care-multidisciplinary-and-patient-perspectives-2026a1000hui?page=1&amp;src=mkmcmr_driv_stan_mscpedu_261118-OUS-HONC-voices-care-multidisciplinary-and-patient-perspectives-2026a1000hui-cta&amp;uac=148436CN&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='http://elbiruniblogspotcom.blogspot.com/feeds/7082209316798963181/comments/default' title='Enviar comentarios'/><link rel='replies' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/voices-in-care-multidisciplinary-and_02118704274.html#comment-form' title='0 comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/7082209316798963181'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/7082209316798963181'/><link rel='alternate' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/voices-in-care-multidisciplinary-and_02118704274.html' title='Voices in Care: Multidisciplinary and Patient Perspectives on Advanced/Recurrent Endometrial Cancer Authors: Eva-Maria Strömsholm; Rebecca Kristeleit, MBChB, MRCP, PhD; Domenica Lorusso, MD, PhD; Antonio González-Martín, MD, PhD; Claire Lusted, ANP '/><author><name>salud equitativa</name><uri>http://www.blogger.com/profile/07311128648250676366</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='29' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjP1bRvK6r5s9cdQYx6VnhhqYNzD_duyjJALHnoOaMe_O2NvjtFtZbrcVFdjehk2aYq4ID66zSiRhSMBe1afy52ty1Q4xMTT0lTlmQFKLe4qUnVHttO00MqeETdGsjyuw/s220/pagina69.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6133155209720004801.post-305430178397103039</id><published>2026-11-19T09:15:07.727-08:00</published><updated>2026-11-19T09:15:07.727-08:00</updated><title type='text'>ADHD in an underserved context: how Chinese social media users discuss recognition, care, and difficulty Xueyan Cao1 , Yidi Wang2,* (++...)</title><content type='html'>&lt;a href=&quot;https://www.academia.edu/2997-9196/3/3/10.20935/MHealthWellB8513&quot;&gt;https://www.academia.edu/2997-9196/3/3/10.20935/MHealthWellB8513&lt;/a&gt;
Introduction: Attention-deficit/hyperactivity disorder (ADHD) remains under-recognized and underdiagnosed in China, particularly among adolescents and adults. As formal diagnosis and treatment remain difficult to access, ADHD has become increasingly visible on social media platforms such as RedNote, where users share experiences, compare symptoms, and seek information outside clinical settings. Understanding how ADHD is discussed in these spaces is important for mental health literacy, stigma reduction, and pathways to care.

Materials and methods: Using a computational approach, we examined how ADHD is discussed on Chinese social media. We analyzed 47,612 valid user comments from the 50 most-commented posts that were obtained through searching the keyword “ADHD” on RedNote. We used Structural Topic Modeling (STM) to identify latent thematic clusters and Semantic Network Analysis (SNA) to examine how key terms co-occurred across the corpus.

Results: Four themes were identified: school difficulties and family communication; managing attention and task completion; clinical diagnosis and treatment; and academic performance and evaluation concerns. Clinical diagnosis and treatment was the most prevalent theme. The semantic network showed that “oneself” and “ADHD” were the most highly connected terms, and that diagnostic vocabulary co-occurred with everyday language about schooling, self-management, and family life.

Conclusions: On RedNote, ADHD is discussed largely through the language of schooling, academic performance, and family life rather than in strictly clinical terms, with diagnostic language interwoven with first-person accounts of everyday difficulty. These patterns describe how ADHD is collectively discussed and can inform culturally grounded mental health communication and screening for digitally engaged populations. Future interview-based, longitudinal, and cross-platform research could test whether these patterns hold more broadly.
&lt;a href=&quot;https://www.academia.edu/journals/academia-mental-health-and-well-being/articles?source=journal-top-nav&quot;&gt;https://www.academia.edu/journals/academia-mental-health-and-well-being/articles?source=journal-top-nav&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='http://elbiruniblogspotcom.blogspot.com/feeds/305430178397103039/comments/default' title='Enviar comentarios'/><link rel='replies' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/adhd-in-underserved-context-how-chinese.html#comment-form' title='0 comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/305430178397103039'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/305430178397103039'/><link rel='alternate' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/adhd-in-underserved-context-how-chinese.html' title='ADHD in an underserved context: how Chinese social media users discuss recognition, care, and difficulty Xueyan Cao1 , Yidi Wang2,* (++...)'/><author><name>salud equitativa</name><uri>http://www.blogger.com/profile/07311128648250676366</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='29' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjP1bRvK6r5s9cdQYx6VnhhqYNzD_duyjJALHnoOaMe_O2NvjtFtZbrcVFdjehk2aYq4ID66zSiRhSMBe1afy52ty1Q4xMTT0lTlmQFKLe4qUnVHttO00MqeETdGsjyuw/s220/pagina69.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6133155209720004801.post-3963925588501620452</id><published>2026-11-19T09:06:11.252-08:00</published><updated>2026-11-19T09:06:11.252-08:00</updated><title type='text'>Optimizing the Adult NF1 Journey: A Primary Care and Nonspecialist Guide to Surveillance Authors: Eric Legius, MD, PhD; Anna Berghoff, MD, PhD; Victor-Felix Mautner, MD, PhD; Ignacio Blanco, MD, PhD</title><content type='html'>&lt;a href=&quot;https://www.medscape.org/viewarticle/optimizing-adult-nf1-journey-primary-care-and-nonspecialist-2026a1000zq3?page=1&amp;amp;src=mkmcmr_driv_stan_mscpedu_261117-OUS-HONC-optimizing-adult-nf1-journey-primary-care-and-nonspecialist-2026a1000zq3-cta&amp;amp;uac=148436CN&quot;&gt;https://www.medscape.org/viewarticle/optimizing-adult-nf1-journey-primary-care-and-nonspecialist-2026a1000zq3?page=1&amp;src=mkmcmr_driv_stan_mscpedu_261117-OUS-HONC-optimizing-adult-nf1-journey-primary-care-and-nonspecialist-2026a1000zq3-cta&amp;uac=148436CN&lt;/a&gt;</content><link rel='replies' type='application/atom+xml' href='http://elbiruniblogspotcom.blogspot.com/feeds/3963925588501620452/comments/default' title='Enviar comentarios'/><link rel='replies' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/optimizing-adult-nf1-journey-primary_0426240924.html#comment-form' title='0 comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/3963925588501620452'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/3963925588501620452'/><link rel='alternate' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/optimizing-adult-nf1-journey-primary_0426240924.html' title='Optimizing the Adult NF1 Journey: A Primary Care and Nonspecialist Guide to Surveillance Authors: Eric Legius, MD, PhD; Anna Berghoff, MD, PhD; Victor-Felix Mautner, MD, PhD; Ignacio Blanco, MD, PhD'/><author><name>salud equitativa</name><uri>http://www.blogger.com/profile/07311128648250676366</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='29' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjP1bRvK6r5s9cdQYx6VnhhqYNzD_duyjJALHnoOaMe_O2NvjtFtZbrcVFdjehk2aYq4ID66zSiRhSMBe1afy52ty1Q4xMTT0lTlmQFKLe4qUnVHttO00MqeETdGsjyuw/s220/pagina69.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6133155209720004801.post-3895859214638004860</id><published>2026-11-19T09:05:18.549-08:00</published><updated>2026-11-19T09:05:18.549-08:00</updated><title type='text'>Home Gut Microbiome Tests Give Varying Results June 24, 2026 By: Stephanie Servetas</title><content type='html'>&lt;a href=&quot;https://www.nist.gov/blogs/taking-measure/home-gut-microbiome-tests-give-varying-results&quot;&gt;https://www.nist.gov/blogs/taking-measure/home-gut-microbiome-tests-give-varying-results&lt;/a&gt;
Editor’s note: This blog post discusses the scientific study of fecal matter (aka poop). If that’s bothersome to you, you might want to skip this one (or at least not read it while eating). 

You may have heard about companies that claim they can give you lifestyle advice by analyzing a stool sample, similar to how you can decode your DNA with saliva.

A team of microbiologists at NIST recently put these tests … well … to the test using precisely measured stool samples we already had in our labs.</content><link rel='replies' type='application/atom+xml' href='http://elbiruniblogspotcom.blogspot.com/feeds/3895859214638004860/comments/default' title='Enviar comentarios'/><link rel='replies' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/home-gut-microbiome-tests-give-varying.html#comment-form' title='0 comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/3895859214638004860'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/3895859214638004860'/><link rel='alternate' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/home-gut-microbiome-tests-give-varying.html' title='Home Gut Microbiome Tests Give Varying Results June 24, 2026 By: Stephanie Servetas'/><author><name>salud equitativa</name><uri>http://www.blogger.com/profile/07311128648250676366</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='29' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjP1bRvK6r5s9cdQYx6VnhhqYNzD_duyjJALHnoOaMe_O2NvjtFtZbrcVFdjehk2aYq4ID66zSiRhSMBe1afy52ty1Q4xMTT0lTlmQFKLe4qUnVHttO00MqeETdGsjyuw/s220/pagina69.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6133155209720004801.post-7795407676717890328</id><published>2026-11-19T09:04:15.095-08:00</published><updated>2026-11-19T09:04:15.095-08:00</updated><title type='text'>The Gut Microbiome: Measuring Microbes and Setting Standards for Better Health</title><content type='html'>&lt;a href=&quot;https://www.nist.gov/health/gut-microbiome-measuring-microbes-and-setting-standards-better-health&quot;&gt;https://www.nist.gov/health/gut-microbiome-measuring-microbes-and-setting-standards-better-health&lt;/a&gt;

Only about half of the cells in your body are human. The other half are trillions of microbes that thrive on or inside your body to form a group of biological communities known as the human microbiome. These microbial communities can vary greatly in size and character.

The digestive tract hosts the largest number of microbes, forming a complex ecosystem known as the gut microbiome. Concentrated primarily in the large intestine, it consists of thousands of different species of bacteria, viruses, fungi and other microorganisms.

Like a fingerprint, your gut microbiome is entirely unique. It starts developing the moment you are born. Over time, the amount and types of microorganisms change based on factors such as your environment and diet.</content><link rel='replies' type='application/atom+xml' href='http://elbiruniblogspotcom.blogspot.com/feeds/7795407676717890328/comments/default' title='Enviar comentarios'/><link rel='replies' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/the-gut-microbiome-measuring-microbes.html#comment-form' title='0 comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/7795407676717890328'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/7795407676717890328'/><link rel='alternate' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/the-gut-microbiome-measuring-microbes.html' title='The Gut Microbiome: Measuring Microbes and Setting Standards for Better Health'/><author><name>salud equitativa</name><uri>http://www.blogger.com/profile/07311128648250676366</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='29' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjP1bRvK6r5s9cdQYx6VnhhqYNzD_duyjJALHnoOaMe_O2NvjtFtZbrcVFdjehk2aYq4ID66zSiRhSMBe1afy52ty1Q4xMTT0lTlmQFKLe4qUnVHttO00MqeETdGsjyuw/s220/pagina69.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6133155209720004801.post-1004573612532068824</id><published>2026-11-19T09:02:25.438-08:00</published><updated>2026-11-19T09:02:25.438-08:00</updated><title type='text'>FDA Launches the Global Reliance Disclosure Program to Expand Patient Access to Medicines Worldwide</title><content type='html'>&lt;a href=&quot;https://www.fda.gov/news-events/press-announcements/fda-launches-global-reliance-disclosure-program-expand-patient-access-medicines-worldwide?utm_medium=email&amp;amp;utm_source=govdelivery&quot;&gt;https://www.fda.gov/news-events/press-announcements/fda-launches-global-reliance-disclosure-program-expand-patient-access-medicines-worldwide?utm_medium=email&amp;utm_source=govdelivery&lt;/a&gt;
The GRDP launched on Oct. 30, with a President&#39;s Emergency Plan for AIDS Relief (PEPFAR) tentative approval for lenacapavir, a drug indicated for both HIV prevention and treatment. This is an especially meaningful starting point given PEPFAR&#39;s life-saving mission to combat HIV/AIDS in some of the world&#39;s most vulnerable populations. The GRDP is currently available to PEPFAR tentative approvals, excluding tentatively approved abbreviated new drug application products. However, the FDA intends to expand the GRDP in January 2027 to all novel drug and biologics (New Molecular Entity New Drug Applications and 351(a) Biologics License Applications), dramatically broadening the program&#39;s reach and impact.

The FDA also intends to launch a pathway in early 2027 to expedite an applicant’s ability to request their minimally redacted action packages for approved and licensed drugs and biologics, accelerating global access to medicines that are already on the market in the United States and have been found to be safe and effective by the FDA.

The GRDP addresses one of the most persistent and consequential challenges in global health: the gap between regulatory approval in high-capacity countries and patient access in lower-resource settings. When a drug is approved by the FDA, patients in many parts of the world may wait months or years longer for their own national health authority to complete an independent review due to limited regulatory capacity and resources.

Beyond individual product approvals, the GRDP supports global health security. Harmonized regulatory decisions reduce the risk of fragmented or inconsistent product standards across markets, helping to ensure that the same high-quality therapies reach patients regardless of where they live, including here in the United States.</content><link rel='replies' type='application/atom+xml' href='http://elbiruniblogspotcom.blogspot.com/feeds/1004573612532068824/comments/default' title='Enviar comentarios'/><link rel='replies' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/fda-launches-global-reliance-disclosure.html#comment-form' title='0 comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/1004573612532068824'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/1004573612532068824'/><link rel='alternate' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/fda-launches-global-reliance-disclosure.html' title='FDA Launches the Global Reliance Disclosure Program to Expand Patient Access to Medicines Worldwide'/><author><name>salud equitativa</name><uri>http://www.blogger.com/profile/07311128648250676366</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='29' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjP1bRvK6r5s9cdQYx6VnhhqYNzD_duyjJALHnoOaMe_O2NvjtFtZbrcVFdjehk2aYq4ID66zSiRhSMBe1afy52ty1Q4xMTT0lTlmQFKLe4qUnVHttO00MqeETdGsjyuw/s220/pagina69.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6133155209720004801.post-4469708395712041820</id><published>2026-11-19T08:56:31.242-08:00</published><updated>2026-11-19T08:56:31.243-08:00</updated><title type='text'>Yale study explores why arthritis returns after cancer immunotherapy</title><content type='html'>&lt;a href=&quot;https://www.news-medical.net/news/20261118/Yale-study-explores-why-arthritis-returns-after-cancer-immunotherapy.aspx&quot;&gt;https://www.news-medical.net/news/20261118/Yale-study-explores-why-arthritis-returns-after-cancer-immunotherapy.aspx&lt;/a&gt;
When arthritis develops during cancer immunotherapy, swollen hands can make it hard to open a jar or turn a doorknob. Inflammation in the knees can make walking difficult. For some patients, the joint pain and swelling ease, only to return.

These subsequent flares can be severe enough to interrupt cancer immunotherapy, according to Sang Taek Kim, MD, PhD, assistant professor of medicine (rheumatology, allergy &amp; immunology) at Yale School of Medicine, who notes that approximately 20% to 25% of cancer patients will have rheumatological adverse events after receiving immunotherapy. To better understand why the inflammation recurs, he and his colleagues examined what changed inside the joints between initial and subsequent flares.

In their study, published in Cancer Immunology Research, the team found that some groups of immune cells present during the first flare had become numerous by the second flare. The pattern suggests that during the second occurrence of inflammatory arthritis, the immune system may be drawing on its memory of the earlier response.

“When our immune system encounters the same antigens, those responses can get stronger,” explains Kim, who directs the Yale Immunotherapy Adverse Events in Rheumatology Program.

</content><link rel='replies' type='application/atom+xml' href='http://elbiruniblogspotcom.blogspot.com/feeds/4469708395712041820/comments/default' title='Enviar comentarios'/><link rel='replies' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/yale-study-explores-why-arthritis.html#comment-form' title='0 comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/4469708395712041820'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/4469708395712041820'/><link rel='alternate' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/yale-study-explores-why-arthritis.html' title='Yale study explores why arthritis returns after cancer immunotherapy'/><author><name>salud equitativa</name><uri>http://www.blogger.com/profile/07311128648250676366</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='29' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjP1bRvK6r5s9cdQYx6VnhhqYNzD_duyjJALHnoOaMe_O2NvjtFtZbrcVFdjehk2aYq4ID66zSiRhSMBe1afy52ty1Q4xMTT0lTlmQFKLe4qUnVHttO00MqeETdGsjyuw/s220/pagina69.jpg'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-6133155209720004801.post-8973495611822718004</id><published>2026-11-19T08:55:10.109-08:00</published><updated>2026-11-19T08:55:10.109-08:00</updated><title type='text'>Study reveals the combined effect of migraine and smoking on premature stroke, mortality</title><content type='html'>&lt;a href=&quot;https://www.news-medical.net/news/20261118/Study-reveals-the-combined-effect-of-migraine-and-smoking-on-premature-stroke-mortality.aspx&quot;&gt;https://www.news-medical.net/news/20261118/Study-reveals-the-combined-effect-of-migraine-and-smoking-on-premature-stroke-mortality.aspx&lt;/a&gt;
Migraine and smoking were each associated with a higher risk of early stroke in people who had given birth, while participants with both had the highest risk, according to a study published November 18, 2026, in Neurology, the medical journal of the American Academy of Neurology. The study defined early stroke as occurring at age 60 or younger. Researchers also found that smoking was associated with a higher risk of death during the study, whether a person had migraine or not, while the combination of migraine and smoking was associated with the highest risk of death. The study does not prove migraine and smoking cause early stroke and death, it only shows associations.</content><link rel='replies' type='application/atom+xml' href='http://elbiruniblogspotcom.blogspot.com/feeds/8973495611822718004/comments/default' title='Enviar comentarios'/><link rel='replies' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/study-reveals-combined-effect-of.html#comment-form' title='0 comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/8973495611822718004'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/6133155209720004801/posts/default/8973495611822718004'/><link rel='alternate' type='text/html' href='http://elbiruniblogspotcom.blogspot.com/2026/11/study-reveals-combined-effect-of.html' title='Study reveals the combined effect of migraine and smoking on premature stroke, mortality'/><author><name>salud equitativa</name><uri>http://www.blogger.com/profile/07311128648250676366</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='29' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjP1bRvK6r5s9cdQYx6VnhhqYNzD_duyjJALHnoOaMe_O2NvjtFtZbrcVFdjehk2aYq4ID66zSiRhSMBe1afy52ty1Q4xMTT0lTlmQFKLe4qUnVHttO00MqeETdGsjyuw/s220/pagina69.jpg'/></author><thr:total>0</thr:total></entry></feed>